Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026

By Public Technologies
  • Ocugen flagged upcoming presentations of clinical trial results for its modifier gene therapies in eye diseases.
  • Phase 2 ArMaDa trial readouts for OCU410 in geographic atrophy are scheduled for Oct. 9 and Oct. 11, 2026.
  • Management framed the ArMaDa update as covering safety and efficacy outcomes over 12 months, with no metrics disclosed.
  • Phase 1/2 GARDian1 results for OCU410ST in Stargardt disease will also be presented in early October 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300702PRIMZONEFULLFEED9836569) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.